Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure

American Journal of the Medical Sciences

Volumn 332, Issue 3, 2006, Pages 112-118

  Laguardia, Stephen P ^a   Dockery, Brian K ^a   Bhattacharya, Syamal K ^a   Nelson, Maeda D ^a   Carbone, Laura D ^a,b   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

African Americans; Congestive heart failure; Ionized hypocalcemia; Ionized hypomagnesemia; Parathyroid hormone; Vitamin D

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIFEDIOL; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; MAGNESIUM; PARATHYROID HORMONE; SPIRONOLACTONE; VITAMIN D;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DISEASE DURATION; FEMALE; HEART EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTHESIS; ISCHEMIC HEART DISEASE; MAGNESIUM BLOOD LEVEL; MALE; MEDICAL CARE; OUTPATIENT CARE; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;

EID: 33747340892     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200609000-00003     Document Type: Article

References (70)

1. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
2. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
3. Rousseau MF, Gurné O, van Eyll C, et al. Effects of benazeprilat on left ventricular systolic and diastolic function and neurohormonal status in patients with ischemic heart disease. Circulation 1990;81:III123-9.
4. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
5. Villarreal D, Freeman RH, Johnson RA. Neurohormonal modulators and sodium balance in experimental heart failure. Am J Physiol 1993;264:H1187-93.
6. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
7. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, et al. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996;131:146-52.
8. Chen L, Zang Y, Bai B, et al. Electron spin resonance determination and superoxide dismutase activity in polymorphonuclear leukocytes in congestive heart failure. Can J Cardiol 1992;8:756-60.
9. Tsutsui H, Ide T, Hayashidani S, et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 2001;104:134-6.
10. Cesselli D, Jakoniuk I, Barlucchi L, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 2001;89:279-86.
11. Sawyer DB, Siwik DA, Xiao L, et al. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002;34:379-88.
12. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 2003;285:H813-H21.
13. Ahokas RA, Warrington KJ, Gerling IC, et al. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res 2003;93:e124-35.
14. Aukrust P, Ueland T, Müller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-43.
15. Damås JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure: modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001;38:187-93.
16. Damås JK, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure: possible role of platelets and monocytes. Cardiovasc Res 2000;45:428-36.
17. Yndestad A, Damås JK, Eiken HG, et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 2002;54:175-82.
18. Yndestad A, Holm AM, Müller F, et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003;60:141-6.
19. Anker SD, Clark AL, Teixeira MM, et al. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1999;83:612-5.
20. Mann DL, Young JB. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994;105:897-904.
21. Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994;96:35-41.
22. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997;103:197-207.
23. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34.
24. Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 2005;111:871-8.
25. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994;14:219-31.
26. Vidal A, Sun Y, Bhattacharya SK, et al. The calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol 2006;290:H286-94.
27. 2 in peripheral blood mononuclear cells. Circulation 2005;111:51-7.
28. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-81.
29. Chhokar VS, Sun Y, Bhattacharya SK, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2004;287:H2023-6.
30. Law PH, Sun Y, Bhattacharya SK, et al. Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol 2005;46:142-6.
31. Runyan AL, Chhokar VS, Sun Y, et al. Bone loss in rats with aldosteronism. Am J Med Sci 2005;330:1-7.
32. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab 1962;22:1187-92.
33. Gehr MK, Goldberg M. Hypercalciuria of mineralocorticoid escape: clearance and micropuncture studies in the rat. Am J Physiol. 1986; 251:F879-F88.
34. Rastegar A, Agus Z, Connor TB, et al. Renal handling of calcium and phosphate during mineralocorticoid "escape" in man. Kidney Int 1972;2:279-86.
35. Grey A, Mitnick MA, Shapses S, et al. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption: a clinical research center study. J Clin Endocrinol Metab 1996;81:3450-4.
36. Takahashi S, Hakuta M, Aiba K, et al. Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels. Endocr Relat Cancer 2003;10:403-7.
37. Fertig A, Webley M, Lynn JA. Primary hyperparathyroidism in a patient with Conn's syndrome. Postgrad Med J 1980;56:45-7.
38. Hellman DE, Kartchner M, Komar N, et al. Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. JAMA 1980;244:1351-3.
39. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med 1985;78:385-90.
40. Rossi E, Sani C, Perazzoli F, et al. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens 1995;8:884-93.
41. Stefenelli T, Pacher R, Woloszczuk W, et al. Parathyroid hormone and calcium behavior in advanced congestive heart failure [German]. Z Kardiol 1992;81:121-5.
42. Christ E, Linka A, Junga G, et al. Bone density and laboratory parameters of bone metabolism in patients with terminal heart disease [German]. Schweiz Med Wochenschr 1996;126:1553-9.
43. Schmid C, Kiowski W. Hyperparathyroidism in congestive heart failure. Am J Med 1998;104:508-9.
44. Zittermann A, Schleithoff SS, Tenderich G, et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41:105-12.
45. Rousseau MF, Gurne O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002;40:1596-601.
46. Khouzam RN, Dishmon DA, Farah V, et al. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci 2006;331:30-4.
47. Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med 2001;250:144-53.
48. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80:1678S-88S.
49. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
50. Dickerson RN, Alexander KH, Minard G, et al. Accuracy of methods to estimate ionized and "corrected" serum calcium concentrations in critically ill multiple trauma patients receiving specialized nutrition support. JPEN J Parenter Enteral Nutr 2004;28:133-41.
51. Altura BT, Shirey TL, Young CC, et al. Characterization of a new ion selective electrode for ionized magnesium in whole blood, plasma, serum, and aqueous samples. Scand J Clin Lab Invest Suppl 1994;217:21-36.
52. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006;83:754-9.
53. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690-3.
54. Weber KT. Furosemide in the long-term management of heart failure: the good, the bad and the uncertain. J Am Coll Cardiol 2004;44:1308-10.
55. Stein MS, Scherer SC, Walton SL, et al. Risk factors for secondary hyperparathyroidism in a nursing home population. Clin Endocrinol (Oxf) 1996;44:375-83.
56. Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988;67:876-81.
57. Bell NH, Greene A, Epstein S, et al. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 1985;76:470-3.
58. Sawaya BP, Monier-Faugere MC, Ratanapanichkich P, et al. Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol 2002;57:51-5.
59. Glerup H, Mikkelsen K, Poulsen L, et al. Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. J Intern Med 2000;247:260-8.
60. Drueke T, Fauchet M, Fleury J, et al. Effect of parathyroidectomy on left-ventricular function in haemodialysis patients. Lancet 1980;1:112-4.
61. Hara S, Ubara Y, Arizono K, et al. Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Miner Electrolyte Metab 1995;21:72-6.
62. Nasri H, Baradaran A. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. JAMC 2004;16:3-8.
63. Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest 1981;67:1215-27.
64. Bogin E, Levi J, Harary I, et al. Effects of parathyroid hormone on oxidative phosphorylation of heart mitochondria. Miner Electrolyte Metab 1982;7:151-6.
65. Baczynski R, Massry SG, Kohan R, et al. Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int 1985;27:718-25.
66. Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol 1992;263:R734-7.
67. Quintana A, Griesemer D, Schwarz EC, et al. Calcium-dependent activation of T-lymphocytes. Pflugers Arch 2005;450:1-12.
68. Kusec V, Smalcelj R, Puretic Z, et al. Interleukin-6, transforming growth factor-beta 1, and bone markers after kidney transplantation. Calcif Tissue Int 2004;75:1-6.
69. Perna AF, Smogorzewski M, Massry SG. Verapamil reverses PTH- or CRF-induced abnormal fatty acid oxidation in muscle. Kidney Int 1988;34:774-8.
70. Burniston JG, Saini A, Tan LB, et al. Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J Mol Cell Cardiol 2005;39:395-9.